All Stories

  1. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site
  2. Plagues
  3. Hidden reservoirs
  4. Simian Immunodeficiency Virus Infection of Chimpanzees (Pan troglodytes) Shares Features of Both Pathogenic and Non-pathogenic Lentiviral Infections
  5. Host Subtraction, Filtering and Assembly Validations for Novel Viral Discovery Using Next Generation Sequencing Data
  6. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates
  7. Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1
  8. Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance
  9. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge
  10. A helminth-mediated viral awakening
  11. Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion
  12. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
  13. A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1
  14. Full-Length Genome Analyses of Two New Simian Immunodeficiency Virus (SIV) Strains from Mustached Monkeys (C. Cephus) in Gabon Illustrate a Complex Evolutionary History among the SIVmus/mon/gsn Lineage
  15. Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virus
  16. Strong Vaccine-Induced CD8 T-Cell Responses Have Cytolytic Function in a Chimpanzee Clearing HCV Infection
  17. Simian Immunodeficiency Virus Infection of Chimpanzees (Pan troglodytes)
  18. Pathology caused by persistent murine norovirus infection
  19. Loss of memory CD4+ T-cells in semi-wild mandrills (Mandrillus sphinx) naturally infected with species-specific simian immunodeficiency virus SIVmnd-1
  20. In Vitro Neutralization of Low Dose Inocula at Physiological Concentrations of a Monoclonal Antibody Which Protects Macaques against SHIV Challenge
  21. Genetic Imprint of Vaccination on Simian/Human Immunodeficiency Virus Type 1 Transmitted Viral Genomes in Rhesus Macaques
  22. Canine hepacivirus is not associated with chronic liver disease in dogs
  23. what viruses do West African fruit bats carry?
  24. Anti-HIV IgA isotypes
  25. DLA Class II Alleles and Haplotypes Are Associated with Risk for and Protection from Chronic Hepatitis in the English Springer Spaniel
  26. Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants
  27. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein
  28. Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: A proof of concept study in macaques
  29. Control of Simian Immunodeficiency Virus SIVmnd-1 RNA Plasma Viremia after Coinfection or Superinfection with SIVmnd-1 in SIVmnd-2-Infected Mandrills and Vice Versa
  30. Perspectives in HIV Vaccine Development: What we have Learned and how we Proceed Forward
  31. Protection in Macaques Immunized with HIV-1 Candidate Vaccines Can Be Predicted Using the Kinetics of Their Neutralizing Antibodies
  32. A Viral Discovery Methodology for Clinical Biopsy Samples Utilising Massively Parallel Next Generation Sequencing
  33. Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41
  34. Norovirus Regulation of the Innate Immune Response and Apoptosis Occurs via the Product of the Alternative Open Reading Frame 4
  35. Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies
  36. Herpesvirus saimiri infection of rhesus macaques: A model for acute rhadinovirus-induced t-cell transformation and oncogenesis
  37. Molecular Evolution Analysis of the Human Immunodeficiency Virus Type 1 Envelope in Simian/Human Immunodeficiency Virus-Infected Macaques: Implications for Challenge Dose Selection
  38. An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV
  39. No difference in Gag and Env immune-response profiles between vaccinated and non-vaccinated rhesus macaques that control immunodeficiency virus replication
  40. Correction: CD8+ NK cells are predominant in chimpanzees, characterized by high NCR expression and cytokine production, and preserved in chronic HIV-1 infection
  41. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer
  42. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals
  43. Viruses as vaccine vectors for infectious diseases and cancer
  44. Characterization of novel polyomaviruses from Bornean and Sumatran orang-utans
  45. An ill wind for wild chimps?
  46. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques
  47. Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens
  48. Acute-phase CD4+ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques
  49. NKp44 expression, phylogenesis and function in non-human primate NK cells
  50. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge
  51. Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel
  52. Seroprevalence of SV40-like polyomavirus infections in captive and free-ranging macaque species
  53. EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
  54. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
  55. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates
  56. Better Protective Effects in Rhesus Macaques by Combining Systemic and Mucosal Application of a Dual Component Vector Vaccine After Rectal SHIV89.6P Challenge Compared to Systemic Vaccination Alone
  57. HLA Homology within the C5 Domain Promotes Peptide Binding by HIV Type 1 gp120
  58. Rhesus Macaque TRIM5 Alleles Have Divergent Antiretroviral Specificities
  59. Chimpanzee CD4+ T cells are relatively insensitive to HIV-1 envelope-mediated inhibition of CD154 up-regulation
  60. Independent evolution of an antiviral TRIMCyp in rhesus macaques
  61. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic
  62. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian human immunodeficiency virus viraemia with protein/DNA combination
  63. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
  64. Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates
  65. Molecular characterization of the first polyomavirus from a New World primate: squirrel monkey polyomavirus
  66. T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus
  67. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo
  68. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
  69. Old Rhesus Macaques Treated with Interleukin-7 Show Increased TREC Levels And Respond Well to Influenza Vaccination
  70. Characterization of α-Defensins Plasma Levels in Macaca Fascicularis and Correlations with Virological Parameters during SHIV89.6Pcy11 Experimental Infection
  71. Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy
  72. Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection
  73. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques
  74. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity
  75. Immunological correlates of protection from HIV infection and disease
  76. Zoonotic viral diseases and the frontier of early diagnosis, control and prevention
  77. Sustained Conservation of CD4+ T Cells in Multiprotein Triple Modality-Immunized Rhesus Macaques after Intrarectal Challenge with Simian Immunodeficiency Virus
  78. Origins of HIV and the Evolution of Resistance to AIDS
  79. Transmission of Simian Immunodeficiency Virus SIVcpz and the Evolution of Infection in the Presence and Absence of Concurrent Human Immunodeficiency Virus Type 1 Infection in Chimpanzees
  80. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection
  81. Importance of the N-Distal AP-2 Binding Element in Nef for Simian Immunodeficiency Virus Replication and Pathogenicity in Rhesus Macaques
  82. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
  83. Modulation of Vaccine‐Induced Immune Responses to Hepatitis C Virus in Rhesus Macaques by Altering Priming before Adenovirus Boosting
  84. Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy
  85. Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates
  86. The Phylogeography of Orangutan Foamy Viruses Supports the Theory of Ancient Repopulation of Sumatra
  87. Direct Inoculation of Simian Immunodeficiency Virus from Sooty Mangabeys in Black Mangabeys (Lophocebus aterrimus): First Evidence of AIDS in a Heterologous African Species and Different Pathologic Outcomes of Experimental Infection
  88. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens
  89. T‐cell‐mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge
  90. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys
  91. Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope
  92. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection
  93. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
  94. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses
  95. Nef Proteins from Simian Immunodeficiency Virus-Infected Chimpanzees Interact with p21-Activated Kinase 2 and Modulate Cell Surface Expression of Various Human Receptors
  96. Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA
  97. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge
  98. Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection
  99. Increase in plasmacytoid and myeloid dendritic cells by progenipoietin-1, a chimeric Flt-3 and G-CSF receptor agonist, in SIV-Infected rhesus macaques
  100. Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA–CD62L–CCR7– memory T-helper cells
  101. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
  102. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120
  103. Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response
  104. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection
  105. Experimental norovirus infections in non-human primates
  106. A novel simian immunodeficiency virus isolated from a Schmidt's guenon (Cercopithecus ascanius schmidti)
  107. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment
  108. Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines
  109. Structural and Evolutionary Analysis of an Orangutan Foamy Virus
  110. Foci of Endemic Simian Immunodeficiency Virus Infection in Wild-Living Eastern Chimpanzees (Pan troglodytes schweinfurthii)
  111. Specific nature of cellular immune responses elicited by chimpanzees against HIV-1
  112. Gene therapy in nonhuman primate models of human autoimmune disease
  113. Reduced transmission and prevalence of simian T-cell lymphotropic virus in a closed breeding colony of chimpanzees (Pan troglodytes verus)
  114. Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine
  115. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of ?-chemokines in contrast to infected humans
  116. Replication, Immunogenicity, and Protective Properties of Live-Attenuated Simian Immunodeficiency Viruses Expressing Interleukin-4 or Interferon-γ
  117. T-Cell Receptor:CD3 Down-Regulation Is a Selected In Vivo Function of Simian Immunodeficiency Virus Nef but Is Not Sufficient for Effective Viral Replication in Rhesus Macaques
  118. Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees
  119. In vitro susceptibility to infection with SIVcpz and HIV-1 is lower in chimpanzee than in human peripheral blood mononuclear cells
  120. The critical role of CD4+ T-cell help in immunity to HIV
  121. Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 in Rhesus macaques
  122. In Vitro Replication of SIVcpz Is Suppressed by β-Chemokines and CD8+ T Cells But Not by Natural Killer Cells of Infected Chimpanzees
  123. SIVcpz in Wild Chimpanzees
  124. Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques
  125. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins
  126. Differences in early virus loads with different phenotypic variants of HIV-1 and SIVcpz in chimpanzees
  127. Editorial
  128. Rhesus macaque and chimpanzee DC-SIGN act as HIV/SIV gp120 trans-receptors, similar to human DC-SIGN
  129. Characteristics of a Pathogenic Molecular Clone of an End-Stage Serum-Derived Variant of Simian Immunodeficiency Virus (SIVF359)
  130. Simian Immunodeficiency Virus in Which nef and U3 Sequences Do Not Overlap Replicates Efficiently In Vitro and In Vivo in Rhesus Macaques
  131. No Evidence of HIV and SIV Sequences in Two Separate Lots of Polio Vaccines Used in the First U.S. Polio Vaccine Campaign
  132. Protection from Secondary Human Immunodeficiency Virus Type 1 Infection in Chimpanzees Suggests the Importance of Antigenic Boosting and a Possible Role for Cytotoxic T Cells
  133. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
  134. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1
  135. Independence of Herpesvirus-Induced T Cell Lymphoma from Viral Cyclin D Homologue
  136. Changes in dendritic cell subsets in the lymph nodes of rhesus macaques after application of glucocorticoids
  137. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques
  138. Enhanced Cellular Immune Response and Reduced CD8+ Lymphocyte Apoptosis in Acutely SIV-Infected Rhesus Macaques after Short-Term Antiretroviral Treatment
  139. Mucosal Exposure to Subinfectious Doses of SIV Primes Gut-Associated Antibody-Secreting Cells and T Cells: Lack of Enhancement by Nonneutralizing Antibody
  141. Genetic variability of the V1 and V2env domains of SIVcpz-ant and neutralization pattern of plasma viruses in a chimpanzee infected naturally
  142. Herpesvirus Saimiri vFLIP Provides an Antiapoptotic Function but Is Not Essential for Viral Replication, Transformation, or Pathogenicity
  143. Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees
  144. Suppression of Acute Viremia by Short-Term Postexposure Prophylaxis of Simian/Human Immunodeficiency Virus SHIV-RT-Infected Monkeys with a Novel Reverse Transcriptase Inhibitor (GW420867) Allows for Development of Potent Antiviral Immune Responses Resu...
  145. Evidence for Viral Virulence as a Predominant Factor Limiting Human Immunodeficiency Virus Vaccine Efficacy
  146. Antiretroviral Therapy during Primary Immunodeficiency Virus Infection Can Induce Persistent Suppression of Virus Load and Protection from Heterologous Challenge in Rhesus Macaques
  147. A strategy for cloning infectious molecular clones of retroviruses from serum or plasma
  148. Co‐receptor Usage of BOB/GPR15 in Addition to CCR5 Has No Significant Effect on Replication of Simian Immunodeficiency Virus In Vivo
  149. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques
  150. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
  151. Immune correlates of protection from HIV and AIDS – more answers but yet more questions
  152. The Acidic Region and Conserved Putative Protein Kinase C Phosphorylation Site in Nef Are Important for SIV Replication in Rhesus Macaques
  153. Differential cytotoxic T-lymphocyte (CTL) responses in HIV-1 immunised sibling chimpanzees with shared MHC haplotypes
  154. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
  155. The Relative Resistance of HIV Type 1-Infected Chimpanzees to AIDS Correlates with the Maintenance of Follicular Architecture and the Absence of Infiltration by CD8+ Cytotoxic T Lymphocytes
  156. Cellular vaccines
  157. β-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
  158. Cytotoxic T Cells and Neutralizing Antibodies Induced in Rhesus Monkeys by Virus-like Particle HIV Vaccines in the Absence of Protection from SHIV Infection
  159. Generation of CD8 suppressor factor and β chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques
  160. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection
  161. A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen
  162. Comparison ofin Vitroandin VivoInfectivity of Different Clade B HIV-1 Envelope Chimeric Simian/Human Immunodeficiency Viruses inMacaca mulatta
  163. Long Terminal Repeat U3 Length Polymorphism of Human Foamy Virus
  164. European contribution to the science, prevention and management of HIV infection
  165. Immune correlates of protection from HIV infection and AIDS
  166. The effect of recombinant human interferon α BD compared to interferon α 2b on SIV infection in rhesus macaques
  167. Lymphocytes Are the Major Reservoir for Foamy Viruses in Peripheral Blood
  168. Editorial
  169. Comparative analysis of apoptosis in HIV-infected humans and chimpanzees: relation with lymphocyte activation
  170. Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS
  171. The role of major histocompatibility complex polymorphisms on SIV infection in rhesus macaques
  172. Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis
  173. Primate models for AIDS vaccine development
  174. AIDS: a disease of impaired Th-cell renewal?
  175. Virologic and Serologic Characteristics of a Natural Chimpanzee Lentivirus Infection
  176. Comparison of the Response to T-cell Activation by Integrated HIV-1 and HTLV-1 LTR-lacZ Vectors
  177. Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories
  178. Detection of human T-cell leukaemia virus 1 permissive cells using cell lines producing selectable recombinant virions
  179. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells
  180. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines
  181. Different proliferative response of human and chimpanzee lymphocytes after contact with human immunodeficiency virus type 1 gp120
  182. Cytochemical analysis of human T cell leukaemia virus 1 LTR-regulated β-galactosidase gene expression using a novel integrated cell system
  183. Biological and pathological consequences of feline infectious peritonitis virus infection in the cheetah
  184. Bovine ocular squamous cell carcinoma: Ultrastructural characteristics in vitro
  185. Preface
  186. Ebola: The Plague of 2014/2015
  187. Foreword